Sunstone has supported and funded companies that have been the originator of 20 life-changing products

Since the inception in 2007, Sunstone Life Science Ventures (Sunstone) has co-created, supported and funded life science companies that have been the originator of 20 life-changing products approved for the treatment or diagnosis of patients with cardiovascular, respiratory and infectious diseases, as well as cancer, neurological diseases, and those requiring surgical intervention.

While striving to provide a return on investment for our LPs, we are indeed most proud when we make a difference to patients in need of new and better treatment options. At the end of the day, we cannot think of any higher pursuit than helping patients suffering from difficult-to-treat diseases.

We saw a perfect example earlier this year when Chiesi Farmaceutici S.p.A. announced that the FDA had approved Lamzede® for the treatment of non-central nervous system manifestations of alpha-mannosidosis. Alpha-mannosidosis is an ultra-rare, progressive lysosomal storage disorder caused by a deficiency in the enzyme α-mannosidase. Lamzede® was developed by Sunstone portfolio company Zymenex A/S, which was acquired by Chiesi when Lamzede® was in the middle of a phase 3 study. Our kudos to Chiesi Farmaceutici, to Giacomo Chiesi heading the acquisition, to the Zymenex team and to Zymenex CEO @Jens Fogh.

Here is a list of all 20 approved products developed by Sunstone funded life science companies:

Zealand Pharma A/S

  • Lyxumia® (lixisenatide): A GLP-1 receptor agonist developed by Zealand Pharma and marketed by Sanofi
  • Zegalogue® (dasiglucagon): A glucagon receptor agonist for the treatment of severe hypoglycemia in people with diabetes. Marketed by Novo Nordisk.

Zymenex A/S

  • Lamzede®: A novel enzyme replacement for the treatment of non-central nervous system manifestations of alpha-mannosidosis. Marketed by Chiesi Farmaceutici S.p.A.

Nordic Vaccine A/S

  • Posintro™: A saponin based adjuvant technology now part of the Novavax Matrix-M™ technology and applied in the Novavax RSV and COVID-19 Vaccines

Arcoma AB

  • OMNERA 500A®: A digital X-ray System with New Intelligent Automation Features. Marketed by Canon Medical Systems.
  • Arcoma Precision i5®: A new high-end digital X-ray system.
  • Arcoma Intuition®: A versatile digital radiography system that combines outstanding image quality with clinical flexibility for a wide range of digital radiography applications.
  • Arcoma X-ray Cube®: A standalone self-supporting x-ray solution that enables quick installation of an X-ray system in, for example, a temporary hospital.

Acarix A/S

  • CADScor®System: An AI-powered acoustic diagnostic aid to diagnose coronary artery disease.

Evolva AG

  • Veri-te™ resveratrol: A compound that occurs naturally in red wine, grapes and other plants. Evolva’s resveratrol is a high-purity ingredient made via fermentation.

Euro Diagnostica A/S (now Svar Life Science AB):

  • iLite®: A cell-based reporter gene system including among others an Fc Effector Activity Bioassays (ADCC, ADCP) and T-Cell Activation Bioassays

Asante Inc.

  • Asante Snap™: An innovative insulin pump using standard insulin cartridges. Asante Snap™ is no longer marketed.

Chempaq A/S

  • Chempaq XBC eXpress™: Blood Counter & Analyzer. Chempaq XBC eXpress™ is no longer marketed.

Vivostat A/S

  • Vivostat® System: An operating room equipment that allows preparation of autologous Fibrin Sealant or Platelet Rich Fibrin (PRF)
  • Vivostat® Fibrin Sealant
  • Vivostat® PRF (Platelet Rich Fibrin): second generation platelet product Vivostat® PRF (Platelet Rich Fibrin)

JenaValve AG

  • Trilogy Heart Valve System: Approved for commercial use in the European Union for patients with Severe Aortic Regurgitation and Stenosis

Atonomics A/S (Now Qlife Holding AB)

  • The Egoo Device: A point of care device with the potential to measure several health-related parameters. Currently available for CRP

Egalet Inc (then Lyla, now Assertion)

  • AXAYDO: an abuse-deterrent oxycodone formulation for pain management.
What do you think?
Let us know in our feed on LinkedIn:

5 latest press releases

Hans T. Scambye joins Sunstone as Venture Partner

Sunstone is delighted to announce that experienced biotech executive and CEO of Galecto Hans T. Schambye will be joining our team as new Venture Partner as of 1st February 2025. With a background as an MD and PhD Hans brings to Sunstone over 25 years of experience...

Neumirna Therapeutics secures euro 20M in Series A financing

Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the first closing of its Series A funding round at €20M. The investment was co-led by new investors, Angelini...

Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that liver imaging drug candidate, Orviglance®, significantly improved visualization of focal liver lesions, successfully...

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk

Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of...

A Sunstone team update

After 17 years as General Partner and co-founder of Sunstone Life Science Ventures and almost 40 years in the life science industry, our colleague Sten Verland will be taking on a part-time role as Venture Partner as of February 1. Sten will continue to manage his...

5 latest articles

Are Series A radically growing?

If you are in the biotech venture capital business, it’s been difficult to avoid conversations about the increasing sizes of Series A financing rounds. We’ve been hearing and reading about a revival of biotech financing, including “Biotech Financing: darkest before...

Saving Lives with Venture Capital

In 2023 we posted our thoughts on how to calculate the potential lifesaving impact of biotech venture capital (https://bit.ly/3z4mL0o) – and we promised to expand on the topic. Unfortunately, or rather fortunately, we got busy making investments in DioGenX, Kynexis...

The VC summer dream – the Fund Returner

The VC summer dream – the Fund ReturnerSunstone has over the past years continuously highlighted observations and learnings from successes in European biotech. The learnings have consolidated, tuned and verified our current investment strategy. Sunstone is today...

Are we making a tangible difference?

We are a Life Science Venture Capital with a passion for investing in drug development, both because it is extremely exciting but also because we contribute to moving new therapies closer to patients with severe, untreated diseases – we matter! – we make a tangible...

Biotech startups in Scandinavia have 460 MEUR at hand – but burn is up – and runway the shortest in 3 years

As the market continues to fluctuate and geopolitical issues continue to impact the economy, it's important to take a closer look at the state of pre-commercial life science companies. At Sunstone, we assisted companies in our portfolio with listings and refinancing,...

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?  For the past 5 months we have had the pleasure of having Philip Brainin as intern at Sunstone Life Science Ventures. Apart from bringing valuable insights to our daily activities, he has...